Search Site

Search form

Current Press Releases

All Releases
View Summary Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014
Sep 8, 2014
PDF 67.0 KB
View Summary Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10
Sep 2, 2014
PDF 6.8 KB
View Summary Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations
Jul 31, 2014
PDF 20.4 KB
View Summary Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs
Jul 29, 2014
PDF 64.9 KB
View Summary Vertex to Announce Second Quarter 2014 Financial Results on July 29
Jul 14, 2014
PDF 6.9 KB
View Summary Vertex Announces Retirement of Peter Mueller, Ph.D.
Jul 10, 2014
PDF 8.7 KB
View Summary Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation
Jun 30, 2014
PDF 19.5 KB
View Summary Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations
Jun 27, 2014
PDF 20.3 KB
View Summary Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation
Jun 24, 2014
PDF 76.2 KB
View Summary Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza
Jun 18, 2014
PDF 15.6 KB
View Summary Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO® (ivacaftor) in Canada for Eligible People with Cystic Fibrosis
Jun 16, 2014
PDF 20.1 KB
View Summary Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data at European Cystic Fibrosis Society Conference
Jun 12, 2014
PDF 24.3 KB
View Summary Proof-of-Concept Study of Ivacaftor Monotherapy Showed Improvements in Lung Function After Two Weeks of Treatment in People with Cystic Fibrosis who have a Residual Function Mutation
Jun 4, 2014
PDF 25.6 KB
View Summary Vertex to Present at the Goldman Sachs Global Healthcare Conference on June 10
Jun 3, 2014
PDF 6.7 KB
View Summary Vertex to Present at the UBS Global Healthcare Conference on May 20
May 13, 2014
PDF 6.7 KB
View Summary William Young Joins Vertex Board of Directors
May 7, 2014
PDF 7.5 KB
View Summary Addition of VX-661 to KALYDECO® (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study
May 1, 2014
PDF 24.4 KB
View Summary Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities
May 1, 2014
PDF 49.9 KB
View Summary Vertex to Announce First Quarter 2014 Financial Results on May 1
Apr 10, 2014
PDF 7.0 KB
View Summary Vertex to Present at the Barclays Global Healthcare Conference on March 11
Mar 6, 2014
PDF 7.3 KB
Showing 1-20 of 27 Page: 1 2  Next 20